

Michael Borre

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3123050/michael-borre-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

214
papers

7,517
citations

46
h-index

80
g-index

220
ext. papers

9,221
ext. citations

6
avg, IF

5.65
L-index

#	Paper	IF	Citations
214	Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by Ga-PSMA PET/CT.. <i>Diagnostics</i> , 2022 , 12,	3.8	1
213	Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling.. <i>Genome Medicine</i> , 2022 , 14, 9	14.4	1
212	The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer.. <i>Genome Medicine</i> , 2022 , 14, 8	14.4	1
211	An inverse association between plasma benzoxazinoid metabolites and PSA after rye intake in men with prostate cancer revealed with a new method.. <i>Scientific Reports</i> , 2022 , 12, 5260	4.9	
210	Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol.. <i>BMJ Open</i> , 2022 , 12, e050264	3.64	0
209	Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 214-220	8.9	25
208	Acute urinary retention and risk of cancer: population based Danish cohort study. <i>BMJ, The</i> , 2021 , 375, n2305	5.9	0
207	In vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit Jun. <i>Oncogene</i> , 2021 , 40, 2437-2447	9.2	6
206	High-Throughput and Automated Acoustic Trapping of Extracellular Vesicles to Identify microRNAs With Diagnostic Potential for Prostate Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 631021	5.3	3
205	Internet-delivered Mindfulness-Based Cognitive Therapy for anxiety and depression in cancer survivors: Predictors of treatment response. <i>Internet Interventions</i> , 2021 , 23, 100365	4.4	3
204	Safety and Effects of Football in Skeletal Metastatic Prostate Cancer: a Subgroup Analysis of the FC Prostate Community Randomised Controlled Trial. <i>Sports Medicine - Open</i> , 2021 , 7, 27	6.1	2
203	Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study. <i>BJU International</i> , 2021 , 128, 702-712	5.6	
202	Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2021 , 398, 131-142	4.0	27
201	FRMD6 has tumor suppressor functions in prostate cancer. <i>Oncogene</i> , 2021 , 40, 763-776	9.2	11
200	Tumour blood flow for prediction of human prostate cancer aggressiveness: a study with Rubidium-82 PET, MRI and Na/K-ATPase-density. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 532-542	8.8	4
199	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021 , 53, 65-75	36.3	62
198	Potential synergy between PSMA uptake and tumour blood flow for prediction of human prostate cancer aggressiveness. <i>EJNMMI Research</i> , 2021 , 11, 12	3.6	2

197	Prostate Cancer Screening-The Need for and Clinical Relevance of Decision Analytical Models. <i>JAMA Network Open</i> , 2021 , 4, e212182	10.4	1
196	Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors. <i>Journal of Pathology</i> , 2021 , 255, 155-165	8.4	7
195	Deep Learning Improves Speed and Accuracy of Prostate Gland Segmentations on Magnetic Resonance Imaging for Targeted Biopsy. <i>Journal of Urology</i> , 2021 , 206, 604-612	2.5	3
194	Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential. <i>Cells</i> , 2020 , 9,	7.9	6
193	Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome. <i>Scientific Reports</i> , 2020 , 10, 10704	4.9	2
192	Internet-delivered mindfulness-based cognitive therapy for anxiety and depression in cancer survivors: A randomized controlled trial. <i>Psycho-Oncology</i> , 2020 , 29, 68-75	3.9	26
191	Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study. <i>Cancer Causes and Control</i> , 2020 , 31, 139-151	2.8	2
190	Renal cryoablation - does deep endophytic ablation affect the renal collecting system?. <i>Scandinavian Journal of Urology</i> , 2020 , 54, 33-39	1.6	2
189	Patient-reported outcome measures after treatment for prostate cancer: Results from the Danish Prostate Cancer Registry (DAPROCAdata). <i>Cancer Epidemiology</i> , 2020 , 64, 101623	2.8	9
188	Positive Predictive Value of Benign Prostatic Hyperplasia and Acute Urinary Retention in the Danish National Patient Registry: A Validation Study. <i>Clinical Epidemiology</i> , 2020 , 12, 1281-1285	5.9	2
187	Renal cryoablation: five- and 10-year survival outcomes in patients with biopsy-proven renal cell carcinoma. <i>Scandinavian Journal of Urology</i> , 2020 , 54, 408-412	1.6	2
186	The power of empirical data; lessons from the clinical registry initiatives in Scandinavian cancer care. <i>Acta Oncologica</i> , 2020 , 59, 1343-1356	3.2	5
185	Renal Potassium Excretion Visualized on Rubidium PET/CT. <i>Nuclear Medicine and Molecular Imaging</i> , 2020 , 54, 120-122	1.9	2
184	Profiling of Circulating microRNAs in Prostate Cancer Reveals Diagnostic Biomarker Potential. <i>Diagnostics</i> , 2020 , 10,	3.8	12
183	Epigenetic silencing of MEIS2 in prostate cancer recurrence. <i>Clinical Epigenetics</i> , 2019 , 11, 147	7.7	7
182	Repeatability of tumor blood flow quantification with Rubidium PET/CT in prostate cancer test-retest study. <i>EJNMMI Research</i> , 2019 , 9, 58	3.6	5
181	Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells. <i>American Journal of Pathology</i> , 2019 , 189, 2377-2388	5.8	15
180	Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial. <i>PLoS Medicine</i> , 2019 , 16, e1002936	11.6	23

179	Quantitative Tumor Perfusion Imaging with Rb PET/CT in Prostate Cancer: Analytic and Clinical Validation. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 1059-1065	8.9	15
178	A novel combined miRNA and methylation marker panel (miMe) for prediction of prostate cancer outcome after radical prostatectomy. <i>International Journal of Cancer</i> , 2019 , 145, 3445-3452	7.5	9
177	Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e814-e821	3.3	7
176	Home-based Exergaming Was safe and significantly improved 6-min walking distance in patients with prostate cancer: a single-blinded randomised controlled trial. <i>BJU International</i> , 2019 , 124, 600	5.6	13
175	A five-microRNA model (pCaP) for predicting prostate cancer aggressiveness using cell-free urine. <i>International Journal of Cancer</i> , 2019 , 145, 2558-2567	7.5	16
174	Long-term Somatic Disease Risk in Adult Danish Cancer Survivors. <i>JAMA Oncology</i> , 2019 , 5, 537-545	13.4	7
173	5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	3
172	Causes of death in men with prostate cancer: Results from the Danish Prostate Cancer Registry (DAPROCAdata). <i>Cancer Epidemiology</i> , 2019 , 59, 249-257	2.8	11
171	Aberrant , , and Hypermethylation has Potential as a Prognostic Biomarker for Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	19
170	Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1051-1061	2.2	104
169	Independent Validation of a Diagnostic Noninvasive 3-MicroRNA Ratio Model () for Prostate Cancer in Cell-Free Urine. <i>Clinical Chemistry</i> , 2019 , 65, 540-548	5.5	14
168	The relationship between tumor aggressiveness and cholinergic PET imaging in prostate cancer tissue. A proof-of-concept study. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 9, 185-192	2.2	4
167	Active Surveillance for Localized Prostate Cancer: Nationwide Observational Study. <i>Journal of Urology</i> , 2019 , 201, 520-527	2.5	10
166	Use of Low-Dose Aspirin and Mortality After Prostate Cancer Diagnosis: A Nationwide Cohort Study. <i>Annals of Internal Medicine</i> , 2019 , 170, 443-452	8	9
165	Football Compared with Usual Care in Men with Prostate Cancer (FC Prostate Community Trial): A Pragmatic Multicentre Randomized Controlled Trial. <i>Sports Medicine</i> , 2019 , 49, 145-158	10.6	27
164	Soluble HER3 predicts survival in bladder cancer patients. <i>Oncology Letters</i> , 2018 , 15, 1783-1788	2.6	4
163	Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies. <i>Molecular Oncology</i> , 2018 , 12, 545-560	7.9	32
162	Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. <i>European Urology</i> , 2018 , 73, 870-876	10.2	23

161	Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine. <i>European Urology Focus</i> , 2018 , 4, 825-833	5.1	55
160	Prostate cancer: in-bore magnetic resonance guided biopsies at active surveillance inclusion improve selection of patients for active treatment. <i>Acta Radiologica</i> , 2018 , 59, 619-626	2	11
159	Long-term urodynamic findings following radical prostatectomy and salvage radiotherapy. <i>Scandinavian Journal of Urology</i> , 2018 , 52, 20-26	1.6	5
158	Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results. <i>Journal of Urology</i> , 2018 , 199, 459-464	2.5	11
157	Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients. <i>Annals of Oncology</i> , 2018 , 29, 2003-2009	10.3	18
156	Scandinavian Prostate Cancer Patients' Sexual Problems and Satisfaction With Their Sex Life Following Anti-Cancer Treatment. <i>Sexual Medicine</i> , 2018 , 6, 210-216	2.7	8
155	Perceptions about screening for prostate cancer using genetic lifetime risk assessment: a qualitative study. <i>BMC Family Practice</i> , 2018 , 19, 32	2.6	4
154	Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer. <i>Clinical Epigenetics</i> , 2018 , 10, 105	7.7	24
153	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018 , 50, 928-936	36.3	340
152	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , 2018 , 9, 2256	17.4	57
151	Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5006-5006	2.2	9
150	Non-invasive quantification of tumor blood flow in prostate cancer using O-HO PET/CT. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 8, 292-302	2.2	7
149	Adverse effect of docetaxel versus surveillance after radical prostatectomy for high risk prostate cancer: Post-hoc analysis of the prospective randomized, open-label phase III SPCG 12 trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 30-30	2.2	
148	Multi-parametric magnetic resonance imaging monitoring patients in active surveillance for prostate cancer: a prospective cohort study. <i>Scandinavian Journal of Urology</i> , 2018 , 52, 8-13	1.6	12
147	Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2639-2646	2.2	85
146	Reply to M. Nayan et al. <i>Journal of Clinical Oncology</i> , 2018 , 36, 629-630	2.2	
145	Exploring the transcriptome of hormone-naïve multifocal prostate cancer and matched lymph node metastases. <i>British Journal of Cancer</i> , 2018 , 119, 1527-1537	8.7	5
144	Robot-assisted laparoscopic cystectomy with intracorporeal urinary diversion vs. open mini-laparotomy cystectomy: evaluation of surgical inflammatory response and immunosuppressive ability of CO ₂ -pneumoperitoneum in an experimental porcine study. <i>Scandinavian Journal of Urology</i> , 2018 , 52, 249-255	1.6	1

143	A lifestyle intervention among elderly men on active surveillance for non-aggressive prostate cancer: a randomised feasibility study with whole-grain rye and exercise. <i>Trials</i> , 2017 , 18, 20	2.8	11
142	Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients. <i>Scientific Reports</i> , 2017 , 7, 40636	4.9	25
141	Arterial Clamping Increases Central Renal Cryoablation Efficacy: An Animal Study. <i>Technology in Cancer Research and Treatment</i> , 2017 , 16, 414-420	2.7	5
140	Computed Tomography Perfusion, Magnetic Resonance Imaging, and Histopathological Findings After Laparoscopic Renal Cryoablation: An In Vivo Pig Model. <i>Technology in Cancer Research and Treatment</i> , 2017 , 16, 406-413	2.7	6
139	Evaluation of robot-assisted laparoscopic versus open cystectomy and effect of carbon dioxide-pneumoperitoneum on histopathological findings in ureteroenteric anastomoses: results from an experimental randomized porcine study. <i>Scandinavian Journal of Urology</i> , 2017 , 51, 50-56	1.6	0
138	Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3290-3297	2.2	49
137	Postoperative C-reactive protein concentration and clinical outcome: comparison of open cystectomy to robot-assisted laparoscopic cystectomy with extracorporeal or intracorporeal urinary diversion in a prospective study. <i>Scandinavian Journal of Urology</i> , 2017 , 51, 381-387	1.6	11
136	Perioperative Systemic Inflammatory Response following Robot-Assisted Laparoscopic Cystectomy vs. Open Mini-Laparotomy Cystectomy: A Prospective Study. <i>Urologia Internationalis</i> , 2017 , 99, 436-445	1.9	10
135	Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer. <i>Scandinavian Journal of Urology</i> , 2017 , 51, 457-463	1.6	4
134	Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. <i>European Urology</i> , 2017 , 71, 151-154	10.2	202
133	Oncological outcomes and complication rates after laparoscopic-assisted cryoablation: a European Registry for Renal Cryoablation (EuRECA) multi-institutional study. <i>BJU International</i> , 2017 , 119, 390-395	5.6	12
132	RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy. <i>Oncotarget</i> , 2017 , 8, 5774-5788	3.3	20
131	Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	17
130	A phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate-specific antigen (PSA) progression in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5004-5004	2.2	6
129	Bioactive small molecules in commercially available cereal food: Benzoxazinoids. <i>Journal of Food Composition and Analysis</i> , 2017 , 64, 213-222	4.1	6
128	Long-term efficacy and safety of enzalutamide (ENZ) monotherapy in hormone-naïve prostate cancer (HNPC): 3-year, open-label, follow-up results.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 220-220	2.2	
127	Molecular imaging of cholinergic processes in prostate cancer using ^{11}C -donepezil and ^{18}F -FEOBV. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 906-910	8.8	2
126	Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma. <i>Molecular Oncology</i> , 2016 , 10, 1450-1460	7.9	32

125	Shared care in prostate cancer: a three-year follow-up. <i>Scandinavian Journal of Urology</i> , 2016 , 50, 346-51	1.6	4
124	Benzoxazinoids in Prostate Cancer Patients after a Rye-Intensive Diet: Methods and Initial Results. <i>Journal of Agricultural and Food Chemistry</i> , 2016 , 64, 8235-8245	5.7	10
123	Parkinson's disease and risk of prostate cancer: A Danish population-based case-control study, 1995-2010. <i>Cancer Epidemiology</i> , 2016 , 45, 157-161	2.8	11
122	Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness. <i>BJU International</i> , 2016 , 118, 646-53	5.6	28
121	Exercise-based pre-rehabilitation is feasible and effective in radical cystectomy pathways-secondary results from a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2016 , 24, 3325-31	3.9	52
120	Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. <i>Cancer Cell</i> , 2016 , 30, 27-42	4.3	325
119	Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. <i>European Urology</i> , 2016 , 70, 75-82	10.2	123
118	Preoperative Aspects and Dimensions Used for Anatomical Score Predicts Treatment Failures in Laparoscopic Cryoablation of Small Renal Masses. <i>Journal of Endourology</i> , 2016 , 30, 537-43	2.7	6
117	Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels. <i>Molecular Oncology</i> , 2016 , 10, 825-37	7.9	18
116	A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer: Results of SPCG12.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5001-5001	2.2	6
115	HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer. <i>Oncotarget</i> , 2016 , 7, 74734-74746	3.3	31
114	Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling. <i>Oncotarget</i> , 2016 , 7, 30760-71	3.3	53
113	Preoperative Nutritional Status And the Impact on Radical Cystectomy Recovery: An International Comparative Study. <i>Urologic Nursing</i> , 2016 , 36, 133	1.3	6
112	The Danish Prostate Cancer Database. <i>Clinical Epidemiology</i> , 2016 , 8, 649-653	5.9	4
111	The Impact of Husbands' Prostate Cancer Diagnosis and Participation in a Behavioral Lifestyle Intervention on Spouses' Lives and Relationships With Their Partners. <i>Cancer Nursing</i> , 2016 , 39, E1-9	2.6	7
110	Diagnostic and Therapeutic Strategies for Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2016 , 46, 484-490	4.0	37
109	Salvage radiation therapy following radical prostatectomy. A national Danish study. <i>Acta Oncologica</i> , 2016 , 55, 598-603	3.2	15
108	Danish multidisciplinary cancer groups - DMCG.dk benchmarking consortium: Article series on cancer survival and mortality in Denmark 1995-2012. <i>Acta Oncologica</i> , 2016 , 55 Suppl 2, 1	3.2	

107	Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma. <i>Cancer Research</i> , 2016 , 76, 5894-5906	10.1	65
106	Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk: a nationwide study. <i>Cancer Causes and Control</i> , 2016 , 27, 1067-79	2.8	20
105	Does comorbidity interact with prostate cancer to increase mortality? A Danish cohort study of 45 326 prostate cancer patients diagnosed during 1995-2011. <i>Acta Oncologica</i> , 2016 , 55, 611-8	3.2	7
104	Reduction of quality of life in prostate cancer patients: experience among 6200 men in the Nordic countries. <i>Scandinavian Journal of Urology</i> , 2016 , 50, 330-7	1.6	14
103	Benzoxazinoids: Cereal phytochemicals with putative therapeutic and health-protecting properties. <i>Molecular Nutrition and Food Research</i> , 2015 , 59, 1324-38	5.9	56
102	Survival and PSA-markers for mortality and metastasis in nonmetastatic prostate cancer treated with androgen deprivation therapy. <i>Cancer Epidemiology</i> , 2015 , 39, 623-32	2.8	8
101	Efficacy of a multiprofessional rehabilitation programme in radical cystectomy pathways: a prospective randomized controlled trial. <i>Scandinavian Journal of Urology</i> , 2015 , 49, 133-41	1.6	86
100	Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results. <i>European Urology</i> , 2015 , 68, 787-94	10.2	24
99	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 1121-9	4	46
98	Variation in general practice prostate-specific antigen testing and prostate cancer outcomes: an ecological study. <i>International Journal of Cancer</i> , 2015 , 136, 435-42	7.5	24
97	Computed Tomography Contrast Enhancement Following Renal Cryoablation--Does it Represent Treatment Failure?. <i>Journal of Endourology</i> , 2015 , 29, 1353-60	2.7	11
96	Patient comorbidity is associated with conservative treatment of localized prostate cancer. <i>Scandinavian Journal of Urology</i> , 2015 , 49, 366-70	1.6	6
95	Length of life gained with surgical treatment of prostate cancer: A population-based analysis. <i>Scandinavian Journal of Urology</i> , 2015 , 49, 275-81	1.6	1
94	Outpatient endoscopic treatment of ureteric stones: Five years experience in a self-contained outpatient surgery unit. <i>Scandinavian Journal of Urology</i> , 2015 , 49, 395-9	1.6	3
93	Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy. <i>Scientific Reports</i> , 2015 , 5, 16018	4.9	53
92	High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer. <i>Clinical Epigenetics</i> , 2015 , 7, 111	7.7	24
91	Prostate cancer, comorbidity, and the risk of venous thromboembolism: A cohort study of 44,035 Danish prostate cancer patients, 1995-2011. <i>Cancer</i> , 2015 , 121, 3692-9	6.4	18
90	Co-expression of HER3 and MUC1 is associated with a favourable prognosis in patients with bladder cancer. <i>BJU International</i> , 2015 , 115, 163-5	5.6	10

89	Regional differences in cardiovascular status and events in prostate cancer patients treated with a gonadotrophin-releasing hormone agonist vs antagonist: Results of a pooled analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16096-e16096	2.2	
88	Profiling of circulating microRNAs for prostate cancer biomarker discovery. <i>Drug Delivery and Translational Research</i> , 2014 , 4, 19-30	6.2	70
87	Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. <i>Clinical Cancer Research</i> , 2014 , 20, 2169-81	12.9	74
86	Statin use and risk of prostate cancer: a Danish population-based case-control study, 1997-2010. <i>Cancer Epidemiology</i> , 2014 , 38, 42-7	2.8	37
85	Changes in preoperative characteristics in patients undergoing radical prostatectomy--a 16-year nationwide analysis. <i>Acta Oncologica</i> , 2014 , 53, 361-7	3.2	8
84	Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties. <i>Cancer Research</i> , 2014 , 74, 5758-71	10.1	195
83	A dual program for translation regulation in cellular proliferation and differentiation. <i>Cell</i> , 2014 , 158, 1281-1292	56.2	278
82	External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 1804-12	4	37
81	Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2014 , 15, 592-600	21.7	59
80	Mutational context and diverse clonal development in early and late bladder cancer. <i>Cell Reports</i> , 2014 , 7, 1649-1663	10.6	94
79	Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. <i>European Urology</i> , 2014 , 65, 704-9	10.2	103
78	Multidisciplinary rehabilitation can impact on health-related quality of life outcome in radical cystectomy: secondary reported outcome of a randomized controlled trial. <i>Journal of Multidisciplinary Healthcare</i> , 2014 , 7, 301-11	2.8	40
77	Quality of venous thromboembolism diagnoses among prostate cancer patients in the Danish National Registry of Patients. <i>Clinical Epidemiology</i> , 2014 , 6, 351-7	5.9	13
76	Oncological outcome after primary prostate cryoablation compared with radical prostatectomy: a single-centre experience. <i>Scandinavian Journal of Urology</i> , 2014 , 48, 27-33	1.6	2
75	Survival after radical prostatectomy for clinically localised prostate cancer: a population-based study. <i>BJU International</i> , 2014 , 113, 541-7	5.6	15
74	Penile vibratory stimulation in the recovery of urinary continence and erectile function after nerve-sparing radical prostatectomy: a randomized, controlled trial. <i>BJU International</i> , 2014 , 114, 111-7	5.6	31
73	Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. <i>Scandinavian Journal of Urology</i> , 2014 , 48, 268-75	1.6	56
72	High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer. <i>BMC Cancer</i> , 2014 , 14, 638	4.8	20

71	High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy. <i>BMC Cancer</i> , 2014 , 14, 859	4.8	24
70	Enzalutamide monotherapy: Extended follow-up of a phase II study in hormone-naive prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 62-62	2.2	2
69	Enzalutamide monotherapy: One-year extended follow-up of a phase 2 study in hormone-naive prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5068-5068	2.2	
68	The HER4 isoform JM-a/CYT2 relates to improved survival in bladder cancer patients but only if the estrogen receptor β s not expressed. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2013 , 73, 503-13	2	5
67	Reply to C. Mary Schooling, Grace Sembajwe and Ilir Agalliu letter to the editor Re: Christina G. Jespersen, Mette N \ddot{e} gaard, Michael Borre. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. <i>European Urology</i> , 2013 , 64, e61	10.2	4
66	Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. <i>American Journal of Pathology</i> , 2013 , 182, 339-49	5.8	56
65	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. <i>Human Molecular Genetics</i> , 2013 , 22, 408-15	5.6	109
64	DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3250-8	2.2	102
63	Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer. <i>British Journal of Cancer</i> , 2013 , 108, 420-8	8.7	37
62	Comorbidity and survival of Danish prostate cancer patients from 2000-2011: a population-based cohort study. <i>Clinical Epidemiology</i> , 2013 , 5, 47-55	5.9	9
61	Shared care is a model for patients with stable prostate cancer. <i>Danish Medical Journal</i> , 2013 , 60, A4691	3.8	4
60	Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer. <i>BJU International</i> , 2012 , 110, E287-92	5.6	46
59	Downregulation of zinc finger protein 132 in prostate cancer is associated with aberrant promoter hypermethylation and poor prognosis. <i>International Journal of Cancer</i> , 2012 , 130, 885-95	7.5	20
58	Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. <i>American Journal of Pathology</i> , 2012 , 180, 1824-34	5.8	60
57	miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. <i>BMC Medical Genomics</i> , 2012 , 5, 40	3.7	77
56	Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. <i>BJU International</i> , 2012 , 110, E1228-36	5.6	77
55	Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation. <i>PLoS ONE</i> , 2012 , 7, e46297	3.7	86
54	Completeness of bladder cancer staging in the Danish Cancer Registry, 2004-2009. <i>Clinical Epidemiology</i> , 2012 , 4 Suppl 2, 25-31	5.9	12

53	Completeness of prostate cancer staging in the Danish Cancer Registry, 2004-2009. <i>Clinical Epidemiology</i> , 2012 , 4 Suppl 2, 17-23	5.9	15
52	Validity of the recorded codes of gonadotropin-releasing hormone agonist treatment and orchiectomies in the Danish National Patient Registry. <i>Clinical Epidemiology</i> , 2012 , 4, 145-9	5.9	9
51	Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. <i>International Journal of Cancer</i> , 2012 , 131, 2320-31	7.5	91
50	Quality of urological cancer diagnoses in the Danish National Registry of Patients. <i>European Journal of Cancer Prevention</i> , 2012 , 21, 545-51	2	16
49	Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. <i>Modern Pathology</i> , 2012 , 25, 902-10	9.8	44
48	Clinico-Pathological Characterization of Hereditary, Familial and Sporadic Prostate Cancer. <i>Open Journal of Urology</i> , 2012 , 02, 38-44	0.2	1
47	Survival of prostate cancer patients in central and northern Denmark, 1998-2009. <i>Clinical Epidemiology</i> , 2011 , 3 Suppl 1, 41-6	5.9	11
46	Efficacy of tele-nursing consultations in rehabilitation after radical prostatectomy: a randomised controlled trial study. <i>International Journal of Urological Nursing</i> , 2011 , 5, 123-130	0.8	8
45	The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study. <i>BJU International</i> , 2011 , 107, 1426-31	5.6	47
44	The influence of cardiovascular morbidity on the prognosis in prostate cancer. Experience from a 12-year nationwide Danish population-based cohort study. <i>BMC Cancer</i> , 2011 , 11, 519	4.8	8
43	Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. <i>International Journal of Cancer</i> , 2011 , 128, 1327-34	7.5	301
42	Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. <i>Clinical Cancer Research</i> , 2011 , 17, 5582-92	12.9	146
41	Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. <i>Nature Genetics</i> , 2011 , 43, 785-91	36.3	243
40	Smarcc1 expression: a significant predictor of disease-specific survival in patients with clinically localized prostate cancer treated with no intention to cure. <i>Scandinavian Journal of Urology and Nephrology</i> , 2011 , 45, 91-6		9
39	A short-term cost-effectiveness study comparing robot-assisted laparoscopic and open retroperitoneal radical prostatectomy. <i>Journal of Medical Economics</i> , 2011 , 14, 403-9	2.4	36
38	miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. <i>Oncogene</i> , 2010 , 29, 1073-84	9.2	123
37	Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. <i>BJU International</i> , 2010 , 106, 966-73	5.6	81
36	Impact of comorbidity on survival of invasive bladder cancer patients, 1996-2007: a Danish population-based cohort study. <i>Urology</i> , 2010 , 75, 393-8	1.6	24

35	Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts. <i>BMC Cancer</i> , 2010 , 10, 646	4.8	48
34	Promoter hypomethylation and upregulation of trefoil factors in prostate cancer. <i>International Journal of Cancer</i> , 2010 , 127, 1857-65	7.5	44
33	Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. <i>Cancer Research</i> , 2009 , 69, 4851-60	10.1	320
32	Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy. <i>Clinical Cancer Research</i> , 2009 , 15, 1400-10	12.9	23
31	High frequency of tumor cells with nuclear Egr-1 protein expression in human bladder cancer is associated with disease progression. <i>BMC Cancer</i> , 2009 , 9, 385	4.8	28
30	Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. <i>European Urology</i> , 2009 , 55, 1118-28	10.2	125
29	Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development. <i>International Journal of Cancer</i> , 2009 , 125, 2095-103	7.5	40
28	Snail1 is over-expressed in prostate cancer. <i>Apmis</i> , 2009 , 117, 196-204	3.4	37
27	Screening by lower urinary tract symptoms vs asymptomatic prostate-specific antigen levels leading to radical prostatectomy in Danish men: tumour characteristics and treatment outcome. <i>BJU International</i> , 2009 , 104, 205-8	5.6	8
26	Percentage of tumour-positive biopsy cores: an independent predictor of extraprostatic disease. <i>Scandinavian Journal of Urology and Nephrology</i> , 2009 , 43, 109-13		3
25	Urethral pressure profile 6 months after radical prostatectomy may be diagnostic of sphincteric incontinence: preliminary data after 12 months follow-up. <i>Scandinavian Journal of Urology and Nephrology</i> , 2009 , 43, 114-8		12
24	The prognostic impact of comorbidities on renal cancer, 1995 to 2006: a Danish population based study. <i>Journal of Urology</i> , 2009 , 182, 35-40; discussion 40	2.5	29
23	Bioinformatic identification of FGF, p38-MAPK, and calcium signalling pathways associated with carcinoma in situ in the urinary bladder. <i>BMC Cancer</i> , 2008 , 8, 37	4.8	5
22	Impact of comorbidity on survival of Danish prostate cancer patients, 1995-2006: a population-based cohort study. <i>Urology</i> , 2008 , 72, 1258-62	1.6	29
21	Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. <i>Lancet Oncology</i> , 2008 , 9, 342-51	21.7	225
20	Body mass index and prognostic markers at radical prostatectomy. <i>Scandinavian Journal of Urology and Nephrology</i> , 2008 , 42, 230-6		8
19	Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. <i>Molecular and Cellular Proteomics</i> , 2008 , 7, 1214-24	7.6	174
18	Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer. <i>International Journal of Cancer</i> , 2008 , 122, 509-19	7.5	18

17	Improved survival of patients with prostate cancer in northern Denmark, 1985-2004. <i>Scandinavian Journal of Urology and Nephrology</i> , 2007 , 41, 308-13		3
16	Secretagogin is a new neuroendocrine marker in the human prostate. <i>Prostate</i> , 2007 , 67, 472-84	4.2	16
15	Genome-wide analysis of allelic imbalance in prostate cancer using the Affymetrix 50K SNP mapping array. <i>British Journal of Cancer</i> , 2007 , 96, 499-506	8.7	47
14	Prostate cancer: to scan or not to scan for lymph node involvement?. <i>Scandinavian Journal of Urology and Nephrology</i> , 2007 , 41, 501-6		2
13	Plasma levels of trefoil factors are increased in patients with advanced prostate cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 807-12	12.9	61
12	Phased array magnetic resonance imaging for staging clinically localised prostate cancer. <i>Acta Oncologica</i> , 2005 , 44, 589-92	3.2	2
11	Comparison of methods of microvascular staining and quantification in prostate carcinoma: relevance to prognosis. <i>Apmis</i> , 2002 , 110, 177-85	3.4	25
10	p53 ACCUMULATION ASSOCIATED WITH bcl-2, THE PROLIFERATION MARKER MIB-1 AND SURVIVAL IN PATIENTS WITH PROSTATE CANCER SUBJECTED TO WATCHFUL WAITING. <i>Journal of Urology</i> , 2000 , 164, 716-721	2.5	34
9	p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. <i>Journal of Urology</i> , 2000 , 164, 716-21	2.5	10
8	Association between in vivo iododeoxyuridine labeling, MIB-1 expression, malignancy grade and clinical stage in human prostate cancer. <i>Apmis</i> , 1998 , 106, 389-95	3.4	6
7	Immunohistochemical determination of tumor angiogenesis measured by the maximal microvessel density in human prostate cancer. <i>Apmis</i> , 1998 , 106, 463-9	3.4	32
6	DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure. <i>Prostate</i> , 1998 , 36, 244-9	4.2	21
5	Tumor cell proliferation and survival in patients with prostate cancer followed expectantly. <i>Journal of Urology</i> , 1998 , 159, 1609-14	2.5	41
4	Erythrocyte sedimentation rate--a predictor of malignant potential in early prostate cancer. <i>Acta Oncologica</i> , 1997 , 36, 689-94	3.2	5
3	The dilemma of prostate cancer--a growing human and economic burden irrespective of treatment strategies. <i>Acta Oncologica</i> , 1997 , 36, 681-7	3.2	21
2	The natural history of prostate carcinoma based on a Danish population treated with no intent to cure 1997 , 80, 917-928		44
1	The natural history of prostate carcinoma based on a Danish population treated with no intent to cure 1997 , 80, 917		4